Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Equity Income (2016 - 2025)

Lineage Cell Therapeutics' Equity Income history spans 9 years, with the latest figure at -$7000.0 for Q4 2025.

  • For Q4 2025, Equity Income fell 177.78% year-over-year to -$7000.0; the TTM value through Dec 2025 reached -$6000.0, changed 0.0%, while the annual FY2025 figure was -$8000.0, 0.0% changed from the prior year.
  • Equity Income reached -$7000.0 in Q4 2025 per LCTX's latest filing, down from $6000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $40000.0 in Q1 2023 to a low of -$517000.0 in Q4 2022.
  • Average Equity Income over 4 years is -$74333.3, with a median of -$6000.0 recorded in 2024.
  • Peak YoY movement for Equity Income: surged 103.29% in 2023, then tumbled 177.78% in 2025.
  • A 4-year view of Equity Income shows it stood at -$517000.0 in 2022, then surged by 103.29% to $17000.0 in 2023, then crashed by 47.06% to $9000.0 in 2024, then crashed by 177.78% to -$7000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Equity Income are -$7000.0 (Q4 2025), $6000.0 (Q3 2025), and -$5000.0 (Q1 2025).